RETINAL DYSTROPHY DUE TO BIALLELIC ABCA4 MUTATIONS

Clinical trials for RETINAL DYSTROPHY DUE TO BIALLELIC ABCA4 MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new RETINAL DYSTROPHY DUE TO BIALLELIC ABCA4 MUTATIONS trials appear

Sign up with your email to follow new studies for RETINAL DYSTROPHY DUE TO BIALLELIC ABCA4 MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First human test: gene injection aims to halt blinding eye disease

Disease control Recruiting now

This is an early safety study testing a new gene therapy called VG801 for people with Stargardt disease, an inherited condition that causes vision loss. The trial will enroll 15 participants, aged 6 and older, who have specific genetic mutations. Doctors will inject the experimen…

Matched conditions: RETINAL DYSTROPHY DUE TO BIALLELIC ABCA4 MUTATIONS

Phase: PHASE1, PHASE2 • Sponsor: VeonGen Therapeutics GmbH • Aim: Disease control

Last updated Apr 02, 2026 09:12 UTC

RETINAL DYSTROPHY DUE TO BIALLELIC ABCA4 MUTATIONS

Get alerted when new RETINAL DYSTROPHY DUE TO BIALLELIC ABCA4 MUTATIONS trials appear

First human test: gene injection aims to halt blinding eye disease